Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 14,141 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Completed Phase 2 Interventional

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00391729
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
23
States / cities
Mesa, Arizona • Lafayette, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

NCT01488929
View directory record Official record
Conditions
Schizophrenia, Negative Symptoms, Cognitive Dysfunction
Interventions
TC-5619, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Garden Grove, California • Glendale, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Nov 7, 2026, 5:15 AM EST
Terminated Phase 3 Interventional Results available

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

NCT01198002
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo Q2W, Placebo Q4W, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Nov 7, 2026, 5:15 AM EST
Active, not recruiting Phase 3 Interventional

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

NCT04468659
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Interventions
Lecanemab, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 2 Interventional

Double Blind Trial in Children With Autism Spectrum Disorder

NCT06058962
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Suramin Sodium
Drug
Lead sponsor
Paxmedica
Industry
Eligibility
4 Years to 17 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 2 Interventional Results available

A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)

NCT03347188
View directory record Official record
Conditions
Post-Traumatic Headache
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

NCT01809327
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Nov 7, 2026, 5:15 AM EST
Not listed Phase 1 Interventional Accepts healthy volunteers

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

NCT01874366
View directory record Official record
Conditions
Overweight, Diabetes Mellitus Type 2 in Obese
Interventions
P11187, Placebo
Drug
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Nov 7, 2026, 5:15 AM EST
Not yet recruiting Phase 1Phase 2 Interventional

dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy

NCT07564102
View directory record Official record
Conditions
Prostate Cancer
Interventions
dMD-002, Control
Device · Other
Lead sponsor
Mochida Medical USA, Inc.
Industry
Eligibility
40 Years to 74 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 3 Interventional Results available

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

NCT01114737
View directory record Official record
Conditions
Phenylketonuria
Interventions
Sapropterin dihydrochloride, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
8 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
26
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 2 Interventional Results available

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

NCT04110145
View directory record Official record
Conditions
Functional Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 5 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Nov 7, 2026, 5:15 AM EST
Recruiting Phase 3 Interventional

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480
View directory record Official record
Conditions
Multiple Myeloma, Secondary Immunodeficiency
Interventions
IGI, 10%
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 3 Interventional Results available

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

NCT04380142
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
70
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Nov 7, 2026, 5:15 AM EST
Recruiting Phase 2Phase 3 Interventional

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673
View directory record Official record
Conditions
Alzheimer's Disease Psychosis
Interventions
ACP-204, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
53
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 2 Interventional Results available

Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

NCT03887429
View directory record Official record
Conditions
Impulse Control Disorders
Interventions
SXC-2023, Placebos
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Lincoln, Nebraska • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy

NCT02762929
View directory record Official record
Conditions
Postoperative Pain, Bunions
Interventions
HTX-011A, Saline Placebo, HTX-011B, HTX-002, Bupivacaine HCl, HTX-009
Drug · Biological
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anaheim, California • Bakersfield, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Nov 7, 2026, 5:15 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

NCT06247345
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
Drug
Lead sponsor
Alzheimer's Disease Expert Lab (ADEL), Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 7, 2026, 5:15 AM EST
Terminated Phase 2 Interventional Results available

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

NCT03318523
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Placebo, BIIB054
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of PRX019 in Healthy Adult Volunteers

NCT06699680
View directory record Official record
Conditions
Healthy Participants Study
Interventions
PRX019, Placebo
Drug
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 7, 2026, 5:15 AM EST
Withdrawn Phase 1 Interventional

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

NCT04574869
View directory record Official record
Conditions
Acute Lung Injury, ALI, COVID-19
Interventions
RLS-0071 10 mg/kg, RLS-0071 40 mg/kg, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Efficacy Study to Evaluate AIV001 in Wound Healing Following Surgical Incision

NCT03639883
View directory record Official record
Conditions
Scar, Incision, Abdominal, Wound (Morphologic Abnormality)
Interventions
AIV001
Drug
Lead sponsor
AiViva BioPharma, Inc.
Industry
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Folsom, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

NCT05037929
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Astegolimab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 90 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
36
States / cities
Dothan, Alabama • Jasper, Alabama • Mobile, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 3 Interventional Results available

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

NCT02679573
View directory record Official record
Conditions
Community Acquired Bacterial Pneumonia
Interventions
Delafloxacin, Moxifloxacin, Linezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Montgomery, Alabama • Newark, Delaware • Coral Gables, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Nov 7, 2026, 5:15 AM EST
Completed Phase 3 Interventional

HKT-500 in the Treatment of Adult Patients With Ankle Sprain

NCT00927641
View directory record Official record
Conditions
Ankle Sprain
Interventions
Ketoprofen Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Nov 7, 2026, 5:15 AM EST